7-(2,4-Dinitrophenylamino)-1-(4-methyl-1-piperazinyl)-naphthalene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-(2,4-Dinitrophenylamino)-1-(4-methyl-1-piperazinyl)-naphthalene
• 英文别名: N-(2,4-dinitrophenyl)-8-(4-methylpiperazin-1-yl)naphthalen-2-amine
• 化学式: C₂₁H₂₁N₅O₄
• 分子量: 407.429
• InChiKey: NHMXSHOECNOGKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  7-amino-1-(4-methyl-1-piperazinyl)-naphthalene 、 1-氯-2,4-二硝基苯 在 碳酸氢钠 、 Brine 、 calcium sulfate 、 乙醚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以to give 0.045 g (54%) of the title compound的产率得到7-(2,4-Dinitrophenylamino)-1-(4-methyl-1-piperazinyl)-naphthalene
  参考文献：
  名称：

  Naphthalene derivatives

  摘要：

  化合物的公式（1），其中R1为公式（II），（III），（IV）或（V）的形式；R2为-R4，-O-R4，-O-S（O）2-R4，-NR4R5，R4-（CH2）b-NH（C═X）-（CH2）c-，R4-（CH2）b-O（C-O）NH-（CH2）c-（C═O）NH-，R4-（C═O）NH-（C═O）NH-，-CH2）b-NH（C═X）-（CH2）c-R4，R4-（CH2）b-O（C═O）CH2）c-，-（CH2）b-O（C═O）-（CH2）c-R4，-NH（C═X）NH-R4，R4-O（C═O）O-，-O（C═O）NH-R4，R4-O（C═O）NH-，-（CH2）b-（C═O-（CH2）c-R4，-NH-S（O）2-R4，-C（OH）R4R5，-CH（OH）-R4，-（C═O）-NR4，-CN，-NO2，取代的C1到C6烷基，取代的或未取代的C1到C6烯基，或取代的或未取代的C1到C6炔基，所述取代基以公式-R4，-R4R5，-O-R4或-S（O）d-R4为取代基；R3为氢，C1到C6烷基，C1到C6烷基芳基或芳基；R4和R5各自独立为（XV），（XVI），（XVII），（XVII）氢，-CF3，C1到C6烷基，C1到C6烷基芳基，但当R2为-R4或-OR4时，R4不是氢或C1到C6烷基，这些化合物是有用的心理治疗药物，是有效的5-羟色胺（5-HT1）激动剂和拮抗剂，可用于治疗抑郁症，焦虑症，进食障碍，肥胖症，药物滥用，集群头痛，偏头痛，疼痛和慢性阵发性半头痛和与血管障碍相关的头痛以及其他由5-羟色胺能神经递质缺乏引起的疾病。这些化合物也可用作中枢作用的降压药和血管扩张剂。

  公开号：

  US20050080090A1

文献信息

• Pyrazinyl-substituted naphthalene derivatives
  申请人：——

  公开号：US20010004669A1

  公开（公告）日：2001-06-21

  Compounds of the formula 1 where R 1 is of the formulae 2 R 2 is —R 4 , —O—R 4 , —O—S (O) 2 —R 4 , —NR 4 R 5 , R 4 —(CH 2 ) b —NH(C═X)—(CH 2 )—, R 4 —(CH 2 ) b —O(C═O)NH—(CH 2 ) c —(C═O)NH—, R 4 (C═O)NH—(C═O)NH—, —(CH 2 ) b —NH(C═X)—(CH 2 ) c —R 4 , R 4 —(CH 2 ) b —O(C═)—(CH 2 ) c —, —(CH 2 ) b —O(C═O)—(CH 2 ) c —R 4 , —NH(C═X)NH—R 4 , R 4 —O(C═O)O—, —O(C═)NH—R 4 , R 4 —O(C═O)NH—, —(CH 2 ) b —(C═0)—(CH 2 ) c —R 4 , —NH—S(O) 2 —R 4 , —C(OH)R 4 R 5 , —CH(OH)—R 4 , —(C═O)—NR 4 R 5 , —CN, —NO 2 , substituted C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkenyl, or substituted or unsubstituted C 1 to C 6 alkynyl, said substituted moieties substituted with a moiety of the formulae —R 4 , —R 4 R 5 , —O—R 4 , or —S(O) d —R 4 . These compounds are useful psychotherapeutics and are potent serotonin (5-HT 1 ) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  公式1的化合物，其中R1是公式2，R2是—R4，—O—R4，—O—S(O)2—R4，—NR4R5，R4—(CH2)b—NH(C═X)—(CH2)c—，R4—(CH2)b—O(C═O)NH—(CH2)c—(C═O)NH—，R4(C═O)NH—(C═O)NH—，—(CH2)b—NH(C═X)—(CH2)c—R4，R4—(CH2)b—O(C═)—(CH2)c—，—(CH2)b—O(C═O)—(CH2)c—R4，—NH(C═X)NH—R4，R4—O(C═O)O—，—O(C═)NH—R4，R4—O(C═O)NH—，—(CH2)b—(C═O)—(CH2)c—R4，—NH—S(O)2—R4，—C(OH)R4R5，—CH(OH)—R4，—(C═O)—NR4R5，—CN，—NO2，取代的C1至C6烷基，取代或未取代的C1至C6烯基，或取代或未取代的C1至C6炔基，所述取代基团被公式—R4，—R4R5，—O—R4或—S(O)d—R4的基团取代。这些化合物是有用的精神治疗剂，并且是强效的血清素（5-HT1）激动剂和拮抗剂，可用于治疗抑郁症、焦虑症、饮食失调、肥胖、药物滥用、丛集性头痛、偏头痛、疼痛和慢性阵发性偏头痛以及与血管疾病相关的头痛，以及其他由血清素神经传递不足引起的疾病。这些化合物还可用作中枢作用抗高血压药和血管扩张剂。
• Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or
  申请人：Pfizer Inc.

  公开号：US05597826A1

  公开（公告）日：1997-01-28

  The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

  本发明涉及包含选择性5-羟色胺再摄取抑制剂（SSRI），优选（1S-顺）-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺，以及5-羟色胺1（5-HT1）受体的激动剂或拮抗剂的新组合物，以及使用这样的组合物治疗或预防情绪障碍，包括抑郁症、季节性情感障碍和情绪恶劣，焦虑障碍，包括广泛性焦虑障碍和恐慌障碍；恐旷症，回避性人格障碍；社交恐惧症；强迫症；创伤后应激障碍；记忆障碍，包括痴呆、遗忘障碍和与年龄相关的记忆减退；饮食行为障碍，包括厌食症和贪食症；肥胖；丛集性头痛；偏头痛；疼痛；阿尔茨海默病；慢性阵发性偏头痛；与血管疾病相关的头痛；帕金森病，包括帕金森病性痴呆、神经阻滞剂诱发的帕金森综合症和迟发性运动障碍；内分泌障碍，如高催乳素血症；血管痉挛（特别是在脑血管中）；高血压；涉及运动和分泌变化的胃肠道疾病；性功能障碍，包括早泄；以及化学依赖性。
• Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
  申请人：PFIZER INC.

  公开号：EP0701819A2

  公开（公告）日：1996-03-20

  The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, and an agonist or antagonist of the serotonin 1 (5-HT₁) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

  本发明涉及含有血清素选择性再摄取抑制剂（SSRI），优选(1S-顺式)4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺的新型组合物、和 5-羟色胺 1（5-HT₁）受体的激动剂或拮抗剂，以及此类组合物用于治疗或预防选自情绪障碍（包括抑郁症、季节性情感障碍和肌张力障碍）、焦虑障碍（包括广泛性焦虑障碍和惊恐障碍）的疾病的用途；恐惧症、回避型人格障碍、社交恐惧症、强迫症、创伤后应激障碍；记忆障碍，包括痴呆症、失忆症和与年龄相关的记忆损伤；进食行为障碍，包括神经性厌食症和神经性贪食症；肥胖症；丛集性头痛；偏头痛；疼痛；阿尔茨海默病；慢性阵发性颅内出血；与血管疾病相关的头痛；帕金森病，包括帕金森病痴呆、神经安定剂诱发的帕金森病和迟发性运动障碍；内分泌失调，如高泌乳素血症；血管痉挛（尤其是脑血管痉挛）；高血压；胃肠道疾病，其中涉及运动和分泌的变化；性功能障碍，包括早泄；以及化学依赖。
• NAPHTHALENE DERIVATIVES
  申请人：PFIZER INC.

  公开号：EP0689536A1

  公开（公告）日：1996-01-03
• US5597826A
  申请人：——

  公开号：US5597826A

  公开（公告）日：1997-01-28